Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC)

Gynecologic Oncology

Volumn 141, Issue 1, 2016, Pages 148-154

  Bernardini, Marcus Q ^a   Gien, Lilian T ^a   Lau, Susie ^b   Altman, Alon D ^c   Gilks, Blake ^d   Ferguson, Sarah E ^a   Köbel, Martin ^e   Samouëlian, Vanessa ^f   Wesa, Mina ^d   Cameron, Anna ^e   Nelson, Gregg ^e   Han, Guangming ^a   Clarke, Blaise ^a   Ho, T C ^a   Panzarella, Tony ^a,g   Atenafu, Eshetu G ^g   McAlpine, Jessica N ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Adjuvant treatment; Endometrial cancer; High risk histology; Serous cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOSARCOMA; CLEAR CELL CARCINOMA; ENDOMETRIAL SEROUS CANCER; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CANCER STAGING; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84958554873     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.02.002     Document Type: Article

References (33)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 1 2013 11 30
2. M.Q. Bernardini, T. May, M.A. Khalifa, A.E. Bland, S. Nofech-Mozes, A. Berchuck, and et al. Evaluation of two management strategies for preoperative grade 1 endometrial cancer Obstet. Gynecol. 114 1 2009 7 15
3. A. Mariani, T.J. Sebo, J.A. Katzmann, G.L. Keeney, P.C. Roche, T.G. Lesnick, and et al. Pretreatment assessment of prognostic indicators in endometrial cancer Am. J. Obstet. Gynecol. 182 6 2000 1535 1544
4. W.T. Creasman, M.F. Kohler, F. Odicino, P. Maisonneuve, and P. Boyle Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium Gynecol. Oncol. 95 3 2004 593 596
5. W.K. Huh, M. Powell, C.A. Leath 3rd, J.M. Straughn Jr., D.E. Cohn, M.A. Gold, and et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy Gynecol. Oncol. 91 3 2003 470 475
6. K.T. Murphy, J. Rotmensch, S.D. Yamada, and A.J. Mundt Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 55 5 2003 1272 1276
7. B.M. Slomovitz, T.W. Burke, P.J. Eifel, L.M. Ramondetta, E.G. Silva, A. Jhingran, and et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol. Oncol. 91 3 2003 463 469
8. G. Sutton, J. Kauderer, L.F. Carson, S.S. Lentz, C.W. Whitney, H. Gallion, and et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study Gynecol. Oncol. 96 3 2005 630 634
9. T.A. Ayeni, J.N. Bakkum-Gamez, A. Mariani, M.E. McGree, A.L. Weaver, M.G. Haddock, and et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas Gynecol. Oncol. 129 3 2013 478 485
10. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, C.C. Warlam-Rodenhuis, and et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma Lancet 355 9213 2000 1404 1411
11. Group As, H. Kitchener, A.M. Swart, Q. Qian, C. Amos, and M.K. Parmar Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study Lancet 373 9658 2009 125 136
12. H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaino, N.M. Spirtos, J.D. Bloss, and et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 92 3 2004 744 751
13. R. Singh Review literature on uterine carcinosarcoma J Cancer Res Ther. 10 3 2014 461 468
14. EORTC/DGCG. Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer. ClinicalTrials.gov Identifier: NCT01244789.
15. NCI/GOG. Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer ClinicalTrials.gov Identifier: NCT00807768.
16. University College L. A Trial of Non-selective Versus Selective Adjuvant Therapy in High Risk Endometrial Cancer (STATEC). ClinicalTrials.gov Identifier: NCT02566811.
17. A. Mariani, M.J. Webb, G.L. Keeney, M.G. Haddock, G. Calori, and K.C. Podratz Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am. J. Obstet. Gynecol. 182 6 2000 1506 1519
18. E. Darai, G. Dubernard, A.S. Bats, D. Heitz, P. Mathevet, H. Marret, and et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study Gynecol. Oncol. 136 1 2015 54 59
19. C.H. Kim, F. Khoury-Collado, E.L. Barber, R.A. Soslow, V. Makker, M.M. Leitao Jr., and et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion Gynecol. Oncol. 131 3 2013 714 719
20. C.N. Chang-Halpenny, S. Natarajan, and J. Hwang-Graziano Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy Gynecol. Oncol. 131 3 2013 598 603
21. N.B. Desai, M.A. Kollmeier, V. Makker, D.A. Levine, N.R. Abu-Rustum, and K.M. Alektiar Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma Gynecol. Oncol. 135 1 2014 49 53
22. M.H. Einstein, M. Frimer, D.Y. Kuo, L.L. Reimers, K. Mehta, S. Mutyala, and et al. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma Gynecol. Oncol. 124 1 2012 21 25
23. I. Vandenput, J. Trovik, I. Vergote, P. Moerman, K. Leunen, P. Berteloot, and et al. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study Int. J. Gynecol. Cancer 21 2 2011 332 336
24. A.J. Chiang, K.J. Yu, K.C. Chao, and N.N. Teng The incidence of isolated para-aortic nodal metastasis in completely staged endometrial cancer patients Gynecol. Oncol. 121 1 2011 122 125
25. W.T. Creasman, C.P. Morrow, B.N. Bundy, H.D. Homesley, J.E. Graham, and P.B. Heller Surgical pathologic spread patterns of endometrial cancer A Gynecologic Oncology Group Study. Cancer. 60 8 Suppl. 1987 2035 2041
26. A.N. Fader, C. Nagel, A.E. Axtell, K.M. Zanotti, J.L. Kelley, K.N. Moore, and et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes Gynecol. Oncol. 112 3 2009 558 562
27. M.G. Kelly, D.M. O'Malley, P. Hui, J. McAlpine, H. Yu, T.J. Rutherford, and et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy Gynecol. Oncol. 98 3 2005 353 359
28. L.A. Cantrell, L. Havrilesky, D.T. Moore, D. O'Malley, M. Liotta, A.A. Secord, and et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma Gynecol. Oncol. 127 1 2012 22 26
29. J. Gonzalez Bosquet, S.A. Terstriep, W.A. Cliby, M. Brown-Jones, J.S. Kaur, K.C. Podratz, and et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas Gynecol. Oncol. 116 3 2010 419 423
30. K.M. Doll, J. Tseng, S.A. Denslow, A.N. Fader, and P.A. Gehrig High-grade endometrial cancer: Revisiting the impact of tumor size and location on outcomes Gynecol. Oncol. 132 1 2014 44 49
31. P.J. Hoskins, N. Le, B. Gilks, A. Tinker, J. Santos, F. Wong, and et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation J. Clin. Oncol. 30 14 2012 1656 1662
32. T. Takada, H. Iwase, C. Iitsuka, H. Nomura, K. Sakamoto, K. Omatsu, and et al. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients Int. J. Gynecol. Cancer 22 4 2012 573 578
33. G. Han, D. Sidhu, M.A. Duggan, J. Arseneau, M. Cesari, P.B. Clement, and et al. Reproducibility of histological cell type in high-grade endometrial carcinoma Mod. Pathol. 26 12 2013 1594 1604